Many partners, already involved in studies within the I-MOVE (Influenza – Monitoring Vaccine Effectiveness in Europe) network, came together as the I-MOVE-COVID-19 consortium, and were successful in a bid for the European Commission H2020 call on “Advancing knowledge for the clinical and public health response to the novel coronavirus epidemic”.
The I-MOVE-COVID-19 consortium aims to obtain epidemiological and clinical information on patients with COVID-19 as well as virological information on SARS-CoV-2, through (a) provision of a flexible surveillance platform (adaptable to the epidemiological situation), (b) res-earch studies and (c) evaluation of public health interventions (e.g. vaccination, antivirals), in order to contribute to the knowledge base, guide patient management, and inform the public health response. This will be achieved through adaptation and expansion of the existing, long-running, Europe-wide influenza surveillance network (I-MOVE) to include COVID-19. The network includes primary care networks, hospitals, and national laboratory reference centres in 10 countries across the WHO European Region.
The I-MOVE-COVID-19 priority activities and research projects will be selected based on ECDC/WHO input and the proposal’s detailed list. These will be conducted by mobilising an existing large European multidisciplinary network, combining the expertise and resources of groups working in surveillance (epidemiological, clinical, virological), respiratory disease research, and evaluation of vaccines/treatments. Through protocol sharing and pooling of European results, questions will be answered which could not be efficiently answered by countries acting alone. The I-MOVE-COVID-19 project will share study results rapidly and widely and contribute to the clinical management of patients, public health preparedness and response to COVID-19.
Click here for more information on the I-MOVE-COVID-19 project, including work packages and the scientific steering committee.
Click here for the I-MOVE-COVID-19 restricted study area.
Partners taking part in I-MOVE-COVID-19
- Public health Institute Albania
- Hôpital UZ Brussels, Belgium
- Public Health England
- University of Oxford/RCGP RSC, UK
- Université Sorbonne, France
- INSERM, France
- Institut Pasteur, France
- Santé Publique France
- Université de Corse Pascal Paoli, France
- Vienna Vaccine Safety Initiative (ViVI), Germany
- HPSC, Ireland
- Lithuanian University of Health Sciences, Lithuania
- NIVEL, The Netherlands
- RIVM, The Netherlands
- INS Ricardo Jorge, Portugal
- DGS Portugal
- INCDMIC Cantacuzino, Romania
- Public Health Scotland
- ISCIII National Centre for Epidemiology, Spain
- ISCIII National Centre for Microbiology, Spain
- ISPL-Navarra, Spain
- Public Health Agency, Sweden
- Epiconcept, France
The I-MOVE-COVID-19 network has received funding from the European Commission (from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 101003673).